Microfluidics technology: future prospects for molecular diagnostics

Roger C Lo
Department of Chemical Engineering, California State University, Long Beach, CA, USA

Abstract: Molecular diagnostic tests have been widely used to detect and quantify biomarkers, such as nucleic acids and proteins, associated with specific health conditions or diseases to obtain the critical information for the healthcare providers and patients to make correct medical decisions. However, existing diagnostic instruments usually require costly reagents, long analysis time, established lab infrastructure, and trained professionals to operate, which limits their availability for large-scale screening applications in developed countries and primary care in developing countries. There is a strong demand for robust, cost-effective, and simple-to-operate instruments for molecular diagnostics. The features of microfluidics, such as short analysis time, reduction in fabrication costs, and low sample/reagent consumption, make it a natural fit for the development of new diagnostic instruments. Herein, selected work is highlighted to provide a snapshot of microfluidic devices developed for molecular diagnostics in the past 5 years, specifically focusing on their applications for the detection of agents clinically relevant to cancers, cardiac conditions, and infectious diseases, and an outlook on how microfluidics technology can be further advanced for applications in this area.

Keywords: microfluidics, micro total analysis systems (µTAS), lab-on-a-chip, molecular diagnostics, point-of-care testing

Introduction

Microfluidics includes the science of studying and controlling the behaviors of fluids and particles at microscale (typically tens to hundreds of micrometers) and the technology of developing methods and devices that can precisely and effectively perform such tasks. For over two decades, microfluidics has found broad applications at the interface of biology, chemistry, engineering, and medicine, such as biodefense, genomics, proteomics, pharmaceuticals, and tissue engineering. Microfluidics has been widely employed to miniaturize analytical methods and biological/chemical processes because of its benefits such as portability, high throughput by parallelization, significant increase in sample process speed, reduction in fabrication costs and sample/reagent volumes (10⁻⁶–10⁻¹₈ L), and enhanced system performance and functionality through the integration of various components onto individual devices. These applications are usually referred to as micro total analysis systems or lab-on-a-chip. The beginning of microfluidics can be traced back to the theoretical work developed for gas chromatography (GC) and liquid chromatography (LC) in the 1950s, which indicates that the separation performance can be improved by reducing the sizes of the column diameters and packing particles. This introduced the use of fused
silica capillaries with diameters in micrometers in those systems. Later, capillary electrophoresis (CE) was developed to replace the conventional slab gel electrophoresis for the separation of charged biomolecules. The high surface-to-volume ratio of capillaries allowed fast heat dissipation to mitigate the Joule heating caused by the applied electric field. Therefore, electrophoretic separations could be performed at much higher electric fields, which led to extremely high speeds and resolutions. Although the benefits of miniaturizing analytical methods were identified, there was no suitable platform for further development of miniaturized analytical systems until the rise of the microelectronics industry. Its silicon-based micromachining processes (including photolithography, etching, and bonding steps) were first developed to fabricate microelectromechanical systems (MEMS) and proved to be a suitable platform for miniaturizing analytical methods, as supported by the success of the first GC air analyzer fabricated on a silicon wafer developed by Terry et al in 1979 (Figure 1A). This merge of analytical methods and miniaturization through microfabrication led to the creation of microfluidics. While the efforts of miniaturizing GC and LC columns continued (Figure 1B), the major success of miniaturizing analytical methods came from microfluidic separation chips based on electrophoresis due to their simpler design of applying an electric potential over a microchannel instead of the high-pressure source required by their GC/LC counterparts. In early 1990s, Manz et al demonstrated the potential of microfluidics to address the issues of conventional analytical methods with their chip-based LC and CE systems with integrated monitoring components. This marked the dawn of the modern microfluidics technology.

The choice of materials and fabrication methods of microfluidic devices are determined by their final applications. The first generation of microfluidic devices was fabricated with silicon and glass using the well-established micromachining processes from the microelectronics industry. Driven by new applications and performance requirements, new materials have been used to fabricate microfluidic devices such as ceramic, steel, Teflon, and paper. For academic research, polydimethylsiloxane (PDMS) is the most common material for microfluidic device fabrication because of its many advantages such as optical transparency, biocompatibility, elasticity, and a simple fabrication process (soft lithography) based on molding approaches. In spite of all the advantages, the commercialization of PDMS chips has limited success due to two major roadblocks. First, the multiple-step fabrication (including curing, access port punching, and assembly) is a mostly manual process that is difficult to be fully automated. As a result, the fabrication cost is high and the production is hard to scale up. Second, the nonstandard user interfaces (usually punched access ports) on PDMS chips are hard to make reliable, leak-free connections, as compared to industrial standards, for example, Luer-Lok and barbed connectors. To address these issues, thermoplastics, such as cyclic olefin copolymers and polystyrene, have been used as alternative materials for microfluidic chips. They can be processed by

![Figure 1](https://www.dovepress.com/)

**Figure 1** Miniaturized analytical systems.

**Notes:** (A) Gas chromatographic air analyzer on a planar silicon wafer. It was composed of a sample injection system, a 1.5 m circular-spiral column (200×30 µm), and a thermal conductivity detector. (B) Liquid chromatography chip fabricated by Manz et al at Hitachi Central Research Laboratories. The silicon/glass chip included an open-tubular separation column (6 µm×2 µm×150 mm) and an integrated platinum electrode detector. Adapted from de Mello AJ. FOCUS On-chip chromatography: the last twenty years. Lab Chip. 2002;2(3):48N–54N. With permission from The Royal Society of Chemistry. © The Royal Society of Chemistry 2002. http://dx.doi.org/10.1039/b207266c.
thermoforming, hot embossing, and injection molding, which makes it possible to mass produce microfluidic chips with integrated connectors. However, injection molding is not an ideal fabrication process for the science community because for high throughput and resolution, it is usually associated with expensive equipment and long turnaround times for the mold fabrication.

Additive manufacturing (commonly known as three-dimensional [3D] printing) was developed in the 1980s and had been of limited use for the general public until the expiration of a key patent in 2009. Since 2010, this technology has drawn more and more attention from the science community as a new tool for microfluidic chip fabrication, as reflected on the increased publications. The advantages of 3D printing for microfluidic chip fabrication are as follows. 1) One-step fabrication: a 3D model of a microfluidic chip can be created with any computer-aided design software, such as AutoCAD and SOLIDWORKS, and then sent to a 3D printer to build the chip through layer-by-layer construction. This fabrication process does not require cleanroom facilities like that for PDMS chips and can be fully automated. In addition, it allows multiple materials to be used and microstructures that are not compatible with conventional fabrication processes. 2) Capability of rapid prototyping: depending on the design complexity, the fabrication of a microfluidic chip can be completed in tens of minutes to a few hours from the digital data to an actual object. This allows researchers to take the “fail fast and often” strategy to significantly shorten the development cycle of microfluidic chips for desired applications and also makes it easier to commercialize viable designs into products. As of now, 3D printing cannot compete with conventional fabrication processes for microfluidic chips in terms of resolution, shape conformity, surface quality, and material availability, but it has shown great promise for future microfluidic chip fabrication. More information on 3D printing is available in several reviews and the references cited therein.

This paper is intended to provide a snapshot of microfluidic devices developed for molecular diagnostics in the past 5 years, specifically focusing on their applications for the detection of agents clinically relevant to cancers, cardiac conditions, and infectious diseases, and an outlook on how microfluidics technology can be further advanced for applications in this area. Due to the diversity in microfluidics technology research and space limit, the author does not aim to provide a thorough and comprehensive review, but to give nonspecialist readers a general idea of how microfluidics technology can be integrated with conventional biomolecular techniques for enhanced performance and portability of molecular diagnostic tests for more effective health care delivery. For interested readers, more details on microfluidics technology for biological/biomedical research and applications can be found in several publications and the references cited therein.

### The need for improved molecular diagnostics

Molecular diagnostics is a collection of diagnostic tests used to assess an individual’s health at the molecular level by detecting and analyzing biological molecules such as nucleic acids (DNA and RNA) and proteins. These biological molecules serve as “biomarkers” (biological markers), which are indicators of biological states that can provide information to assist diagnosis, monitor disease progress, assess treatment responses, and identify the risk factors for disease prevention. For effective health care delivery, early and accurate detection is critical and can increase survivability, improve disease management and treatment outcomes, and ultimately lead to preventive and personalized medicine. Compared to conventional culture-based tests, molecular diagnostic tests have a higher sensitivity and specificity and a much shorter turnaround time. For example, the turnaround time for the diagnosis of sepsis is <10 h for molecular diagnostic tests instead of at least 72 h for culture-based tests (even longer for slow-growing pathogens such as yeasts and anaerobes). In clinical diagnosis, nucleic acids (DNA and RNA) and proteins are the mostly used molecular biomarkers in several general areas, including oncology, genetic disease screening, infectious diseases, coagulation, pharmacogenomics, and human leukocyte antigen typing. There is a strong demand for new molecular diagnostic tests with improved sensitivities, increased accuracy, shorter turnaround time, and low cost. Because of its advantages, microfluidics technology holds the promise for developing such molecular diagnostic tests through miniaturizing molecular diagnostic techniques onto microfluidic devices, as demonstrated by the work described in the following sections.

### Microfluidic devices for nucleic acid-based tests

Polymerase chain reaction (PCR), gel electrophoresis, and hybridization are the techniques widely employed to detect and quantify nucleic acids for the identification of genomic biomarkers, such as mutations, polymorphisms, and epigenetic modifications.
PCR is a technique for amplifying DNA fragments, and each reaction requires a DNA template, complementary primers, DNA polymerase (copying enzyme), deoxynucleotide triphosphates (building blocks for copies), and buffer. The mixture goes through thermal cycling to make DNA copies. Each PCR cycle contains three steps: denaturating (90°C–95°C), annealing (50°C–65°C), and polymerization (72°C–80°C). During denaturing, the double-stranded DNA template is separated into single strands. During annealing, the primers bind to the complementary bases on the single-stranded DNA (ssDNA). During polymerization, DNA polymerase reads the template and matches it with the corresponding deoxynucleotide triphosphates to assemble a complementary strand. The whole process is typically repeated 30–40 times to generate millions of identical copies of the original target DNA for analysis and takes about 2 h on a conventional system. For RNAs, reverse transcriptase PCR is used to amplify a target sequence. A double-stranded complementary DNA is first synthesized from the target RNA sequence with an enzyme, reverse transcriptase, from a retrovirus and then goes through the same PCR process as described earlier.

Gel electrophoresis is a technique for size-selective fractionation of charged target molecules, such as DNA and proteins, in a sieving matrix (“gel”; usually agarose and polyacrylamide) under the influence of an applied electric field. A typical gel electrophoresis run is carried out by injecting a mixture with target molecules of different sizes at the inlet of a gel-filled separation channel, after which the target molecules are transported through the gel under the action of an applied electric field. The migration velocities of the target molecules depend on their sizes, so the mixture separates into zones containing like-sized target molecules that are subsequently detected at a fixed downstream location. These zones provide the information on size differences of the target molecules that have diagnostic relevance. Depending on the sample size and resolution, it takes 45 min to 8 h to complete a separation run on a conventional system.

Hybridization is a technique based on the process where fluorescence-labeled, ssDNA or single-stranded RNA molecules serve as probes to specifically attach to those with complementary sequences, which can be used to obtain sequence-specific genetic information for diagnostic applications. There are three types of probes commonly used for diagnostics: 1) painting probes: they attach to overlapping sequences on a chromosome to apply chosen fluorescence colors; 2) centromeric probes: they target the centromeric region of a specific chromosome to help determine the number of copies of that specific chromosome; and 3) allele-specific probes: they attach to a specific allele sequence that is relevant to diagnostics. Here, we review selected microfluidic devices developed for these techniques.

Polymerase chain reaction

Pekin et al developed a droplet-based microfluidic system based on digital PCR to perform highly sensitive and quantitative detection of mutations in the KRAS oncogene, a tumor biomarker. The device was fabricated with PDMS, and a hydrophobic coating was applied to the inside wall of the microchannels to facilitate droplet generation. The genomic DNA was encapsulated in 9 pL droplets along with two fluorogenic TaqMan® probes, which generated green fluorescent droplets for mutant DNA and red ones for the wild-type DNA. This system enabled the detection of a KRAS mutated gene in a large excess (200,000×) amount of wild-type KRAS genes from cultured cells. By adding probes corresponding to different mutations, this system allowed the simultaneous screening of six common mutations in the KRAS codon in one single run. To test the clinical utility, this system was used to screen seven common KRAS mutations using blood plasma samples from patients with metastatic colorectal cancer (CRC) and successfully identified 14 of the 19 confirmed KRAS mutation cases. This showed the promise for a noninvasive diagnostic technique using only blood plasma instead of biopsies. Klein et al presented a high-throughput microfluidic platform for droplet barcoding and analysis of stem cells before and after leukemia inhibitory factor withdrawal. The microfluidic device was fabricated with PDMS by soft lithography, and the depth of microchannels was 80 µm (Figure 2A). Mouse embryonic cells were encapsulated in droplets with the lysis buffer and reverse transcription (RT) reagents along with hydrogel microspheres carrying barcoding ssDNA. After the cell lysis and RT reaction, the barcoded complementary DNA was sequenced to study the cell population structure and heterogeneous onset of differentiation under leukemia inhibitory factor influence. This platform allowed randomly labeling up to 3,000 cells with 99% unique labels for every 100 µL emulsion (12,000 cells/h) and could be used to identify cell types based on gene expression for clinical samples, such as tumors and tissue microbiopsies. Ferraro et al recently developed a new fully automated, programmable microfluidic platform by integrating droplet RT-quantitative PCR and magnetic tweezers to determine the expression level of the human epidermal growth factor receptor 2 (HER2), a biomarker for the breast cancer, by the quantification of the messenger...
RNA. The microfluidic chips were fabricated with PDMS and connected to two syringe pumps for droplet generation. The RNA purification and RT-PCR were performed in droplets of 250 nL. This platform was tested with samples from both cultured cells and clinically validated patients with breast cancers, and the results were in reasonable agreement with those from conventional tests. Compared to the currently used motorized platforms, the sample consumption for this system was decreased by 100 times, and it only took 3 min to process a sample, which allowed high-throughput applications.

Gel electrophoresis

Zhang et al. developed a microchip-based temperature gradient CE system for the detection of low-abundance $K$-ras mutation, a biomarker for the epidermal growth factor receptor-targeted therapy in CRCs. The microfluidic chip was fabricated with glass and had a cross-channel design with sample loading and separation channels of 1.0 and 4.5 cm, respectively. This system was tested with clinical stool samples from CRC patients. Among the 30 stool samples, 17 (57%) were identified to contain $K$-ras mutations and the...
Microfluidic devices for protein-based tests

Proteins can serve as valuable biomarkers because of their high specificity, involvement in many biological processes, and capability to carry more information after alternative splicing and posttranslational modifications. In addition, many physiologic changes, for example, signal transduction, cell differentiation, and malignant transformation, are controlled posttranscriptionally and do not show at the nucleic acid level. As a result, proteins can provide important information on the biological states by their level of abundance and structural,functional changes in a biological system. However, there are challenges for microfluidics-based protein detection. First, proteins are much more diverse than DNAs and RNAs in both numbers (tens to several millions) and sizes (tens to several millions) and on the background in biological samples, while there is no amplification process equivalent to PCR for nucleic acids. To address these challenges, immunoaffinity-based techniques (“immunoassays”) have been miniaturized onto microfluidic devices for detection and quantification of target proteins by exploiting the high sensitivity and specificity.
of antibody–antigen interactions. As described in the “Microfluidic devices for nucleic acid-based tests” section, gel electrophoresis is also applicable to the separation and detection of proteins for diagnostic applications.

**Immunoassays**

Chikkaveeraiah et al developed a microfluidic electrochemical immunoarray for two cancer biomarkers, prostate-specific antigen and interleukin-6 (IL-6), in human serum samples. The chip was composed of a PDMS microchannel sealed onto a disposable eight-electrode microarray with immobilized capture antibodies. The cancer biomarkers were first extracted from serum samples with magnetic microbeads functionalized with enzyme labels and antibodies. The complex was then loaded into the microchannel to be captured onto the electrode surfaces. The detection and quantification of the biomarkers were achieved by amperometric signals resulting from the electron transfer between electrodes and enzyme labels, which was activated by injecting a solution of mediator and hydrogen peroxide. This assay required only 5 µL of patient serum and 69 min to complete. The LOD was 0.23 pg/mL for prostate-specific antigen and 0.30 pg/mL for IL-6. Later, the same group further optimized its microfluidic array for the simultaneous detection and quantification of four cancer biomarkers: IL-6, IL-8, vascular endothelial growth factor (VEGF), and VEGF-C in diluted serum. The assay time was reduced to 50 min. The LOD reached a range of 5–50 fg/mL.

In clinical applications, enzyme-linked immunosorbent assay (ELISA) is broadly used as a diagnostic tool for its precision, sensitivity, versatility, and quantifiability. Conventional ELISA protocols require multiple steps of adsorption, washing, and incubation of reagents. Chin et al developed a microfluidic ELISA chip, the “mChip”, for the detection of human immunodeficiency virus and syphilis in resource-limited settings. The microfluidic chips were fabricated with transparent polystyrene and cyclic olefin copolymer by injection molding (Figure 3A). The steps of reagent addition and washing were carried out by a bubble-based delivery, where measured plugs of reagents and washing buffers were loaded sequentially onto the chip in a tubing with air bubbles as spacers. A manual syringe was used to provide the vacuum needed for fluid manipulations. It took only 1 µL of unprocessed whole blood and 20 min to complete the diagnosis of human immunodeficiency virus. Signal detection was done with a compact device consisting of low-cost light-emitting diodes (LEDs; $0.50 USD each) and photodetectors ($6.00 USD each). Compared to lab-based ELISA, the mChip had a much lower requirement for equipment and could be easily deployed in remote areas for rapid screening. Park et al reported a fully automatic lab-on-a-disk system for the simultaneous detection of cardiovascular disease biomarkers (high-sensitivity C-reactive protein, cardiac troponin I, and N-terminal pro-B type natriuretic peptide) from whole blood and whole saliva. This system included the lab-on-a-disk and a detection module composed of an LED and a photodiode for absorbance measurements. The disk was made with cyclic olefin copolymer for optical clarity. Microchannels and reaction chambers were fabricated on the bottom layer by CNC micromachining, while the top layer had access ports and ferrowax loading chambers. Before assembling with the double-sided tape, polystyrene beads functionalized with capture antibodies were loaded into the main reaction chambers for a bead-based sandwich ELISA. Fluid manipulations were carried out by the centrifugal force and reversible phase changes of the ferrowax valves. Each disk could be used for the fully automated analysis of six biomarkers from two samples in 20 min and only required a total sample volume of 200 µL. For saliva samples, the LOD was 0.30, 0.51, and 0.24 ng/mL for high-sensitivity C-reactive protein, cardiac troponin I, and N-terminal pro-B type natriuretic peptide, respectively. For blood samples, the LOD was 0.27, 0.27, and 0.32 ng/mL, respectively. This system could be revised for other immunoassays by simply changing the capture antibodies. Li et al developed a nanoporous glass-integrated volumetric bar-chart chip to detect the three biomarkers (CEA, CYFRA 21-1, and SCCA) for non-small cell lung cancer. The chip was composed of a nanoporous glass membrane sandwiched between two glass slides with microstructures fabricated using standard photolithographic techniques (Figure 3B). The membrane had multiple nanopores (average diameter=200 nm) that significantly increased the surface area for immobilizing capture antibodies for the sandwich ELISA reaction. Each chip allowed four assays to run simultaneously. The detection and quantification of the target protein biomarkers were visually represented by the travel distance of red ink bars, which were propelled by the oxygen generated from the reaction between the ELISA probe and H₂O₂. The nanoporous glass-integrated volumetric bar-chart chip was used to test 21 serum samples from cancer patients, and the results were consistent with those acquired from commercial ELISA kits. The LOD was 50 pg/mL, and the total analysis time was 30 min.

First introduced by the Whitesides group, paper (cellulose or cellulose–polymer blends) has been used to fabricate microfluidic devices for bioassays because of its
Figure 3 Microfluidic devices for protein detection.


Abbreviations: BSA, bovine serum albumin; CEA, carcinoembryonic antigen; ELISA, enzyme-linked immunosorbent assay; FITC, fluorescein isothiocyanate; FRET, fluorescence energy transfer; IgG, immunoglobulin G; PNP, platinum nanoparticle; UCNPs, upconversion nanoparticles.
Gel electrophoresis

Huang et al. developed a method based on microchip electrophoresis coupled with laser-induced fluorescence detection to phenotype haptoglobin (Hp), a biomarker for the liver cancer. The microfluidic device was fabricated with glass. The microchannels were 25 µm wide and 50 µm deep and had an effective separation length of 4 cm. Hp was labeled with the fluorescein isothiocyanate dye (excitation wavelength=488 nm, emission wavelength=520 nm) for laser-induced fluorescence detection. The process of separation and detection took 150 s to complete, and the LOD was 0.39 and 0.62 µg/mL for two Hp phenotypes, Hp1-1 and 2-2, respectively. Serum samples from healthy individuals and liver cancer patients were tested, and a decrease in the Hp concentration was confirmed for liver cancer patients. This study demonstrated the potential of a simple, efficient, and fast method for disease diagnosis and proteome research.

Kalish and Phillips used a microchip-based immunoaffinity CE system to detect the presence of CXC chemokines, biomarkers for atopic dermatitis, in frozen biopsy samples from patients. Target CXC chemokines were captured with a disposable immunoaffinity disk, labeled with a fluorescence dye, and separated by microchip electrophoresis. The microfluidic chip was fabricated with glass and had 50 µm wide, 20 µm deep microchannels. The separation length was 35 mm. The whole assay took ~40 min, including the biopsy microdissection, sample pretreatment, and microchip electrophoresis. The LOD ranged from 0.2 to 0.4 pg/mL for each of the six chemokines tested in this study. This system enabled the detection and quantification of chemokines relevant to inflammatory skin lesions in clinical histopathology samples and featured very low sample consumption (200 nL), decreased analysis time, and higher sensitivity.

Lin et al. developed a method for multiplex protein assay based on tunable aptamer and microchip electrophoresis. Aptamers are ssDNA or single-stranded RNA molecules that can specifically bind to preselected targets such as proteins, cells, and metal ions. In this study, they were used to form aptamer–protein complexes that could be separated by microchip electrophoresis according to mobility differences. The microfluidic device was fabricated with quartz and had 88 µm wide, 50 µm deep microchannels with an effective separation length of 23 mm. Three cancer-relevant proteins, thrombin, platelet-derived growth factor-BB (PDGF-BB), and vascular endothelial growth factor 165 (VEGF165), were successfully separated and quantified on this microfluidics-based system. The whole process took 185 s to complete and only required a very low sample volume (2 µL). The LOD was 4.1 nM for thrombin, 1.96 nM for PDGF-BB, and 2.48 nM for VEGF165. The dynamic range was between 5 and 150 nM. This method allowed multiplex protein analysis and could be extended to other biological molecules that can bind to aptamers. In addition to nucleic acids and proteins, lipids, carbohydrates, and metabolites can also serve as useful biomarkers.
in-depth information can be found in several recent reviews and the references cited therein.85–83

**Transitioning to point-of-care testing**

As supported by the work reviewed so far, molecular diagnostic tests can be successfully miniaturized onto microfluidic devices and demonstrated enhanced performance compared to their counterparts at the macroscale. However, there are additional requirements to be considered for building viable diagnostic instruments based on these microfluidic devices for routine clinical applications in the field. Conventional diagnostic instrumentation generally requires established infrastructure, reliable electricity supply, costly reagents, long run time, and trained professionals to operate, which are usually unavailable in developing countries and resource-limited environments. To effectively deliver health care, particularly for infectious disease control, there is a strong demand for the capability of performing rapid and timely diagnostic tests at or near the site of patient care (point-of-care testing [POCT]).84 Developed countries with established health care systems can also benefit from POCT through improved preventive and personalized health care made possible by easily and frequently performing diagnostic assays. For example, the detection and quantification of lipoprotein biomarkers can help better predict the risk of cardiovascular diseases, and the use of the information on specific tumor biomarkers can help doctors develop personalized treatment plans based on individual needs.85,86 To be viable, the platform for POCT must be portable, inexpensive, and easy to operate by nonspecialists without the need for complex equipment and established infrastructure. The assays used must be accurate, reliable, reproducible, and fast in terms of seconds and minutes. The benefits of microfluidics, such as portability, reduction in fabrication costs and sample/reagent volumes, and significant increase in sample process speed, are a natural fit for developing POCT devices. Although there are many successful examples of bioassays miniaturized onto microfluidic devices, many of these microchips still require trained professionals to operate and connections to external equipment, such as microscopes, computers, and fluid pumping systems, to perform their tasks, which make it a major roadblock to further deploy POCT systems for better health care. The solution to this roadblock comes from the mass production of open-source microcontrollers (e.g., Raspberry Pi and Arduino) and consumer electronics devices (e.g., tablets and smartphones). Smartphones are an ideal platform for developing POCT systems, because they mostly come with digital cameras, various sensors, and graphics processing and computing units, along with their coverage and data connectivity almost everywhere in the world (~97% global penetration rate).87 Here, we review selected microfluidics-based POCT systems developed by the integration of miniaturized molecular techniques, open-source electronics, and smartphones.

Wang et al88 developed a microchip ELISA-based system with cell phone imaging to quantify an ovarian cancer biomarker, HE4, in clinical urine samples. The microfluidic device was fabricated with poly(methyl methacrylate) and double-sided adhesive films. Each straight microchannel had access ports on both ends and dimensions of 4x7.5x3.225 mm (Figure 4A). Microchip ELISA was carried out by manually loading samples and reagents into the microchannel for incubation. A cell phone with a customized mobile application was used to acquire the color intensity of the ELISA solution in the microchannel after incubation and to report the results on the screen after data processing. The whole assay required 100 µL of urine samples and 15 min to complete with a detection limit of 19.5 ng/mL. Mancuso et al89 developed a microfluidics-based smartphone accessory for the detection of Kaposi’s sarcoma associated herpesvirus (KSHV) nucleic acids. The microfluidic device was with PDMS and glass and had a 1 cm long microchannel for absorbance measurements. The phone accessory for absorbance measurements consisted of a magnetic latch, LED, photodetector, and an Arduino board that controlled the LED and photodetector (Figure 4B). The phone accessory obtained power from and communicated with the phone through a male micro-USB connector. A customized mobile application was coded to control the whole system and to display results on the screen. KSHV probes were prepared by conjugating gold nanoparticles (average diameter = 15 nm) with oligonucleotides specific to KSHV DNA. The assay was carried out by mixing the probe solution with samples containing the KSHV DNA. After 24 h of incubation, the mixture was loaded onto the microchip for absorbance measurement. The LOD was 1 nM of KSHV DNA. Instead of the common handheld devices, Priye et al90 constructed a lab-on-a-drone system that could perform in-flight PCR isothermally for nucleic acid-based diagnosis (Figure 4C). The analysis instrument consisted of a hand-crank power source, an isothermal heater, a blue excitation LED, a liquid crystal display screen, an Arduino board, and a PCR reactor made with a polycarbonate rod (~20 µL in volume). A smartphone with a customized mobile application was used to perform the fluorescence detection of *Staphylococcus aureus* and λ-φage DNA targets. The whole assay took 20 min to complete and had a detection limit of 1,000 copies/µL. The team also designed and
3D-printed rotor attachments that could be connected to the drone motors to perform centrifuge-based sample processing. This system made it possible to rapidly deploy nucleic acid-based diagnostics using consumer quadcopter drones at a low cost. More in-depth information on POCT systems can be found in recent reviews and the references cited therein.91–93

As supported by the success from academic research, there is great potential for microfluidic molecular diagnostics to be commercially viable.

**Challenges to commercialization**

Commercialization plays a critical role in making microfluidic molecular diagnostics accessible to both health care professionals and regular end users. In 2015, the global molecular
diagnostics market was valued at $6.45 billion USD and is projected to reach 17.9 billion USD by 2024 with an expected compound annual growth rate of 12%,\textsuperscript{34} representing a very large opportunity for microfluidic molecular diagnostics. With advances in microfluidics technology and chemical/biological techniques over the past two decades, a number of companies have made great efforts to translate results from academic research into commercial products (Table 1).\textsuperscript{95,96} However, there are relatively few commercial products available in the market, given the immense interest from both academia and industry. This is because of the lack of a game-changing product (or a “killer application”) that can generate at least hundreds of millions of dollars in revenue,\textsuperscript{97} and thus, many investors would turn to other emerging technologies potentially coming with high revenues, resulting in reduced financial support for new product development. In addition, the fabrication costs remain high, when a product does not have high volume demand to reach economies of scale.

To overcome the barriers to commercialization, researchers need to address two major challenges. 1) Component integration: previous research efforts have been focused on miniaturizing molecular diagnostic techniques onto microfluidic devices, while very little consideration has been given to how they are integrated with other components, such as sample pretreatment, fluid control, power supply, and data acquisition/processing, to make a self-contained, functional instrument. Without careful planning for integration, any efforts to optimize individual components can make them mutually incompatible, when putting them together in the final product. To address this, researchers should consider the final commercial application in the beginning of instrument design and ensure that all components are compatible for integration. 2) Fabrication standardization: for academic research, there are no standard materials and processes for developing microfluidic devices for molecular diagnostic tests. The choice of device materials and fabrication processes usually depends on the target application, which makes it difficult for commercialization, because popular materials in academia are often not compatible with mass production. For example, PDMS is a very popular material for microfluidic devices. However, it is very costly when compared to the common polymers used for industrial applications, such as polycarbonate and poly(methyl methacrylate), and soft lithography is difficult to be fully automated. To address this, researchers need to work with manufacturers to identify suitable materials and fabrication processes, when developing products for microfluidic molecular diagnostics.

### Summary and outlook

For over two decades, a lot of progress has been made in the field of microfluidics, ranging from the science of studying and controlling the behaviors of fluids and particles at microscale to the technology of developing methods and devices that can precisely and effectively perform such tasks. For applications in molecular diagnostics, many bioassays have been successfully miniaturized onto microfluidic devices, with performance better than that of their benchtop counterparts. The commercialization of these bioassays has been moving forward faster over the past few years, driven by the need for full-scale integration and automation of all microfluidic components onto a single instrument that can run a process from sample preparation to final results, that is, the “sample in, answer out” platform. More collaborative and interdisciplinary efforts between academia and industry are still needed to develop true “all-in-one” microfluidic devices that can carry out molecular diagnosis in a simple,

**Table 1** List of selected products for microfluidics-based, molecular diagnostic products in the market

<table>
<thead>
<tr>
<th>Company</th>
<th>Product</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abaxis</td>
<td>Piccolo Xpress</td>
<td>Blood analysis for lipid, gases, electrolytes, and metabolites</td>
</tr>
<tr>
<td>Abbott Point of Care</td>
<td>i-STAT</td>
<td>Hand-held blood analysis for gases, electrolytes, and metabolites</td>
</tr>
<tr>
<td>Alere</td>
<td>Triage MeterPro</td>
<td>Cardiovascular and toxicology assays</td>
</tr>
<tr>
<td>BD</td>
<td>BD MAX</td>
<td>Real-time PCR for pathogen detection</td>
</tr>
<tr>
<td>BioFire Diagnostics</td>
<td>FilmArray</td>
<td>PCR and reverse transcription PCR for respiratory pathogen detection</td>
</tr>
<tr>
<td>Cepheid</td>
<td>GeneXpert System</td>
<td>Detection and quantification of nucleic acids</td>
</tr>
<tr>
<td>Focus Diagnostics</td>
<td>Integrated Cycler and Simplexa molecular assays</td>
<td>Real-time PCR for pathogen detection</td>
</tr>
<tr>
<td>Gyros AB</td>
<td>Gyrolab xPlore</td>
<td>Immunoassays, biomarker monitoring, pharmacokinetics, and toxicokinetics</td>
</tr>
<tr>
<td>Micronics</td>
<td>PanNAT</td>
<td>Nucleic acid amplification assay for pathogen detection</td>
</tr>
<tr>
<td>RainDance Technologies</td>
<td>RainDrop Plus</td>
<td>Droplet PCR for nucleic acid detection and biomarker monitoring</td>
</tr>
<tr>
<td>Roche Diagnostics</td>
<td>cobas Liat</td>
<td>Real-time PCR for pathogen detection</td>
</tr>
<tr>
<td>Sphere Medical</td>
<td>Proxima</td>
<td>Blood analysis for gases and electrolytes</td>
</tr>
</tbody>
</table>

**Abbreviation:** PCR, polymerase chain reaction.
cost-effective way. In addition to technical advances, it is also critical to identify suitable markets for microfluidic molecular diagnostics, particularly niche markets where conventional technologies cannot meet the special requirements from potential customers. The industrial parties with marketing skills should be active in surveying end-user requirements and work with their academic partners based on the feedback to develop products that best address these special requirements. This would significantly help microfluidic molecular diagnostics reach its maximum potential for both commercialization and social impact.

In summary, microfluidics technology, as an enabling platform, has a promising outlook for diagnostic applications because of its potential to make laboratory-based diagnostics more accessible to concerned parties for streamlined health care, improved clinical outcomes, and rapid intervention. We can expect that future advances, particularly in POCT, will have a transformative impact on the global health care system to improve our quality of life, especially for people in developing countries and resource-limited environments.

Acknowledgments
The author thanks the Department of Chemical Engineering and College of Engineering at California State University, Long Beach (CSULB) for their support. This work was supported in part by the CSULB Research, Scholarship, and Creativity Awards (RSCA) and the CSULB Sabbatical Leave Award.

Disclosure
The author reports no conflicts of interest in this work.

References


